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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
nicotine replacement therapy reduces the withdrawal symptom of craving, or urge to 
smoke, in dependent adult smokers during smoking cessation.  
 
STUDY DESIGN: Systematic review of three English language and peer-reviewed 
randomized-controlled trials published in 2009, 2010, and 2011.  
 
DATA SOURCES: One single-blinded randomized-controlled crossover trial, one 
double-blinded, placebo controlled, randomized-controlled crossover trial, and one 
single-blinded, placebo controlled, randomized-controlled crossover trial  
 
OUTCOMES MEASURED: Withdrawal symptoms of craving, irritability, difficulty 
concentrating, and restlessness were measured on a 100mm visual analog scale (VAS). 
Adverse effects (AEs) of mouth and throat irritation, aching jaw, feeling sick, vomiting, 
flatulence/belching, stomachache, heartburn, diarrhea, hiccups, feeling high, feeling 
dizzy, headache, palpitations, sweatiness, and cold hands/feet were measured based upon 
their frequency and strength. One study measured slightly different withdrawal symptoms 
(depressed mood, irritability, restlessness, hunger, and poor concentration) on a Moods 
and Physical Symptoms Scale (MPSS) and time spent with urges and strength of urges on 
a six-point Likert Scale.  This study also measured the adverse effects of feeling unwell, 
nausea, throat irritation, and dizziness on a 10-point scale.  Temporary smoking cessation 
was measured in all three studies. 
 
RESULTS: Thornley et al found that the active pouch significantly decreased craving in 
comparison to placebo.  The gum decreased craving; however, the findings were not 
considered to be statistically significant.  In McRobbie et al, all three types of NRT 
proved to significantly decrease craving in comparison to placebo.  Similarly, Shahab et 
al found that both innovative and older types of NRT decreased craving. The Nicotine 
Cannon was more tolerable than older types of NRT.  Overall, the NRT products caused 
more adverse reactions than placebo, but also led to more cases of temporary smoking 
cessation.  
 
CONCLUSION:  The results of all three studies show that nicotine replacement therapy 
decreases the withdrawal symptom of craving, allowing smokers to be more successful in 
their attempts to quit in the short term.  No one NRT product is significantly better than 
another in decreasing craving.  
  
KEY WORDS: nicotine replacement therapy, withdrawal, smoking cessation, craving  
 
 
 
 
 
 
 INTRODUCTION 
 Nicotine dependence is due to alkaloid nicotine, which is a chemical in cigarettes 
that alters the dopaminergic pathway in the midbrain and trains the brain to require 
nicotine to feel pleasure.  Alkaloid nicotine binds to the naturally occurring nicotinic 
receptors in the human brain and spinal cord, sending a message of reward, or pleasure, 
throughout the body.1 With repeated stimulation of these receptors, a person builds 
tolerance and requires higher levels of nicotine to feel the same positive effects.  This 
unending cycle ultimately leads to the body’s dependence on and addiction to nicotine.  
This paper evaluates three randomized-controlled trials that compare the efficacy of 
various types of nicotine replacement therapy (NRT) with placebo in preventing the 
withdrawal symptom of craving in adult smokers during smoking cessation.  
 Although the alkaloid nicotine is responsible for the addiction to cigarettes, it is 
actually the other toxins (benzene, carbon monoxide, acetic acid, formaldehyde, and 
heavy metals) that are responsible for the negative health effects of smoking.  Cigarette 
smoking directly contributes to patients’ health and frequently complicates chronic 
medical conditions and their treatments.  Individuals who smoke are more likely to suffer 
from chronic pulmonary and cardiovascular diseases and various carcinomas, particularly 
of the lung, kidney, bladder, and cervix.2  Women who smoke during pregnancy have a 
higher rate of spontaneous abortion and are at risk of giving birth to babies who are small 
for gestational age.3 Currently, the prevalence of cigarette smoking in the United States is 
19.3%, with people between the ages of 18 and 64 being more likely to smoke than those 
over age 65.4   Because cigarette smoking is directly responsible for so many health 
problems, it is important for physician assistants to be knowledgeable of both the health 
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consequences of smoking and the smoking cessation options that are available for their 
patients.    
 Although the cost per day varies depending on personal habit, the average cost of 
a pack of cigarettes in the US is $5.51.5  It is important to realize, however, that some 
smokers may have a multi-pack per day habit and could potentially be spending well over 
$10 a day on a product that is only harming them.  In fact, cigarette smoking leads to over 
$100 billion in health care expenses, $67 billion in productivity losses at work, and over 
$100 billion in premature deaths annually.5 Whereas a tobacco addiction can be lifelong, 
treatment with NRT is only a temporary expense that will result in better health outcomes 
in the future.  The average daily cost of NRT varies depending on the type of product one 
uses: nasal spray $3.41, patches $3.91, lozenges $4.98, gum $5.81, and inhaler $6.07.6   
 Approximately 70% of current smokers in the US are interested in smoking 
cessation; however, they lack the knowledge of where to look for help and the emotional 
support that proves to be crucial in the process of smoking cessation.1 Various methods 
of smoking cessation exist, such as behavioral modification, group counseling, 
Bupropion, Chantix, and NRT.  Smoking cessation is an individualized process and may 
require more than one attempt before finding the appropriate method that leads to a 
successful outcome.  
 The withdrawal symptom of craving directly affects a smoker’s ability to quit 
smoking by making it more difficult to resist cigarettes for long periods of time.  By 
using NRT, smokers are able to deliver limited amounts of nicotine to their brains in 
order to decrease their craving and retrain their bodies to function without requiring 
nicotine.   
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OBJECTIVE 
The objective of this selective EBM review is to determine whether or not 
nicotine replacement therapy reduces the withdrawal symptom of craving, or urge to 
smoke, in dependent adult smokers during smoking cessation.   
METHODS  
 Criteria used for the selection of the research articles for this review was based on 
population age (≥ 18 years old) and dependency on cigarette smoking.  It was important 
for studies to include comparisons of various nicotine replacement products (4mg 
Zonnic® oral nicotine pouch, 4mg Nicorette® chewing gum, Zonnic® 1mg/spray mouth 
spray, Zonnic® 2.5mg nicotine lozenge) to the usage of placebo.7,8  One of the articles 
compared an innovative nicotine replacement therapy (the Nicotine Cannon) to older 
NRT products (nicotine inhaler, 4mg nicotine lozenge, and 4mg nicotine mini-lozenge).9 
All articles assessed patient-oriented evidence that matters (POEMs), which included 
withdrawal symptoms, adverse effects of NRT usage, and temporary smoking cessation.  
 The author used the PubMed and Medline databases to search for peer-reviewed 
randomized-controlled trials that were published in the English language within the last 
five years. Important key words that were used included “nicotine replacement therapy,” 
“withdrawal,” “smoking cessation,” and “craving”.  The articles were selected based 
upon their evaluation of POEMs and a participant pool of people ≥18 years old.  
Exclusion criteria comprised of patients less than 18 years of age, those not dependent on 
cigarette smoking, and articles that addressed disease-oriented evidence (DOE).  The 
statistics reported in the studies included 95% confidence intervals (CI), p-values, change 
in mean from the baseline, independent t test, and χ2. The author calculated the numbers 
needed to treat (NNT) and numbers needed to harm (NNH) using the dichotomous data 
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on adverse effects and temporary smoking cessation in order to support the efficacy of 
NRT use in comparison to placebo in preventing the withdrawal symptom of craving.  
 
Table 1. Demographics & Characteristics of Included Studies  
Study Type #  
people 
Mean 
Age  
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Shahab9 
(2011) 
RCT – 
single-
blind, 
crossover  
48 31 Over 18,  
regular smokers 
x at least a year, 
≥5 cigarettes/d,  
in good health; 
not pregnant; 
not current 
users of NRT 
products 
N/A N/A Nicotine 
Cannon; 
Nicotine 
lozenge (4mg); 
Mini-lozenge 
(4mg); 
Nicotine 
inhaler 
 
McRobbie
7 
(2010) 
RCT -
double-
blind, 
crossover
, placebo 
controlle
d 
47 49 18 to 70 years 
old, smoked 15+ 
cigarettes/d for at 
least the last year, 
smoked first 
cigarette within 
30 minutes of 
waking, in good 
health, able to 
read and write 
English and give 
written consent 
 
Recent (previous 6 mo) 
MI, angina, DM, other 
serious medical condition, 
previous severe allergic 
reaction, current chemical 
dependence other than 
nicotine, current 
psychiatric d/o or current 
use of psychotropic drugs, 
chronic oral d/o that would 
prevent the use of oral 
NRT products, current use 
of nicotine products other 
than cigarettes, pregnancy 
or breast feeding, weight 
<45 kg or >120 kg, blood 
pressure BP >180/>100 or 
unwillingness to abstain 
from smoking prior to or 
during the study day  
3 Zonnic 1 
mg/dose mouth 
spray (two 
sprays between 
the cheek and 
gums q1h; 
more 
frequently if 
needed); 
Zonnic 2.5mg 
lozenges;   
Nicorette 4mg 
chewing gum 
(one piece each 
hour; more 
frequently if 
needed) 
Thornley8 
(2009) 
RCT – 
single-
blind, 
crossover
, placebo 
controlle
d 
30 50  Same as 
McRobbie 
(2010) 
Same as McRobbie 
(2010) 
3 Zonnic 4mg 
oral nicotine 
pouch;  
Nicotine 
chewing gum 
(4 mg); one 
pouch/piece of 
gum per hour 
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OUTCOMES MEASURED 
 Outcomes measured across all three studies included withdrawal symptoms, 
adverse effects of NRT usage, and temporary abstinence from smoking throughout the 
duration of the study days.  McRobbie et al and Thornley et al measured the following 
withdrawal symptoms: craving, irritability, difficulty concentrating, and restlessness.  
These were measured on a 100mm visual analog scale (VAS; 0= not at all; 100= 
extremely) every five minutes for a total of 60 minutes after the participant used the NRT 
product.7,8  These researchers also measured the adverse effects (AEs) of  mouth and 
throat irritation, aching jaw, feeling sick, vomiting, flatulence/belching, stomachache, 
heartburn, diarrhea, hiccups, feeling high, feeling dizzy, headache, palpitations, 
sweatiness, and cold hands/feet based upon their frequency (never, often, or sometimes) 
and their strength (weak, moderate, and strong).7,8  The measurement for AEs as well as 
the measurement for temporary smoking cessation were made at the completion of each 
study day.  
 Shahab et al measured the withdrawal symptoms of depressed mood, irritability, 
restlessness, hunger, and poor concentration on a Moods and Physical Symptoms Scale 
(MPSS).  This study also measured time spent with urges and strength of urges to smoke 
on a six-point Likert scale.  Adverse effects, measured on a 10-point scale (0= none; 10= 
extreme), included feeling unwell, nausea, throat irritation, and dizziness.  All of these 
measurements were taken via questionnaire before (0 minutes), during (3, 6, 10 minutes) 
and after NRT usage (13, 16, 20 minutes).9 Temporary smoking cessation was also 
measured at both one and ten hours after NRT usage.  
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 The author focused on the withdrawal symptom of craving; however, the 
dichotomous data on adverse effects and temporary smoking cessation supported the 
research question.  
RESULTS 
 Because the research question focuses on the prevention of craving, only the data 
regarding that withdrawal symptom will be presented in the following section.  The data 
pertaining to two common adverse effects (mouth/throat irritation and feeling sick) as 
well as that of temporary smoking cessation provided support for the research question, 
so that data will be explained here too. 
 Two of the randomized-controlled trials compared various types of NRT to 
placebo and one of the randomized-controlled trials compared a new type of NRT to 
older types of NRT.  The Thornley et al trial consisted of three study days, each separated 
by three days when the participants were instructed to smoke normally.  The McRobbie 
et al trial consisted of four study days, each separated by three days when the participants 
were instructed to smoke normally.  Finally, the Shahab et al trial consisted of four study 
days, each separated by seven days when the participants were instructed to smoke 
normally.  
 In the study by Thornley et al, 27 out of the 30 original participants completed the 
three study days.  It was found that the active nicotine pouch was significantly superior in 
decreasing the participants’ craving than the placebo pouch (p= 0.002); furthermore, 
there was a mean change in craving from baseline of -23.1 for the active pouch and only 
a mean change of -8.7 for the placebo pouch, making the mean difference -14.4 (Table 
2).8 The gum did not significantly decrease craving in comparison to placebo (p= 0.22).  
Table 3 displays the data for treatment effect, showing that in comparison to the placebo 
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(41%), both the gum (52%) and the active pouch (75%) allowed more participants to 
remain abstinent throughout the study days.8 The relative benefit increase (RBI) was 
calculated to be 26.8% for the gum and 82.9% for the pouch; the absolute benefit 
increase (ABI) was 11% for the gum and 34% for the pouch.  Finally, the numbers 
needed to treat (NNT) was nine for the gum and three for the pouch (Table 3).  This 
means that nine people have to use the gum and three people have to use the active pouch 
in order for one person to temporarily abstain from tobacco use.   
 Table 4 displays the data describing two common adverse effects of both types of 
NRT versus placebo.  The gum (33%) and the active pouch (13%) caused more people to 
feel sick than placebo (7%); similarly, the gum (47%) and the active pouch (50%) caused 
more people to experience mouth irritation than placebo (37%).8 The numbers needed to 
harm (NNH) were calculated for the gum and active pouch for both of the adverse 
effects.  The NNH for feeling sick was four for the gum and 17 for the active pouch.  
This means that for every four people that use the gum and for every 17 people that use 
the active pouch, one person will feel sick. The NNH for mouth irritation was 10 for the 
gum and eight for the active pouch (Table 4).   
Table 2. Mean change in craving from baseline to 60 minutes after taking medication8 
Treatment  Mean 
h   
Mean difference with placebo 
(95% CI) 
p-value 
Active pouch  -23.1 -14.4 (-24.1 to  -4.8) 0.002 
Gum  -15.4  -6.7 (-16.4 to 2.9) 0.22 
Placebo -8.7 ------------------ ------------------ 
 
Table 3. Temporary smoking cessation until 5:30pm on study days8 
 
CER EER RBI ABI NNT 
41% Gum: 52% Gum: 26.8% Gum: 11% Gum: 9 
 Active pouch: 75% Active pouch: 82.9% Active pouch: 34% Active pouch: 3 
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Table 4. Adverse effects of the gum and active pouch vs. placebo8 
 
 In the study by McRobbie et al, 44 out of the 47 participants completed all four 
study days.  Table 5 shows that all three NRT products significantly reduced the 
withdrawal symptom of craving more than placebo.  There was a mean change in craving 
from baseline of -24.7 for the lozenge, -25.8 for the gum, and -28.6 for the mouth spray 
in comparison to -8.9 for placebo, making the mean differences -15.8, -16.9, and -19.7 
respectively (Table 5).7  Table 6 displays the data for treatment effect, showing that in 
comparison to the placebo (19%), the lozenge (45%), gum (55%) and the mouth spray 
(53%) allowed more participants to remain tobacco free throughout the study days.7  The 
RBI was calculated to be 137% for the lozenge, 190% for the gum, and 179% for the 
mouth spray; the ABI was 26% for the lozenge, 36% for the gum, and 34% for the mouth 
spray.  Finally, the NNT was four for the lozenge, three for the gum, and three for the 
mouth spray (Table 6).   
 Table 7 displays the data describing two common adverse effects of the NRTs 
versus placebo.  The lozenge (38%), gum (34%), and mouth spray (36%) caused more 
people to feel sick than placebo (4%); similarly, the lozenge (25%), gum (30%), and 
mouth spray (45%) cause more people to experience mouth irritation than placebo (4%).7  
The NNH was calculated for the lozenge, gum, and mouth spray for both of the adverse 
effects.  The NNH for feeling sick was three for all types of NRT (Table 7).  The NNH 
Adverse event CER EER RRI ARI NNH 
Feeling sick 7% Gum: 33% 
Active pouch: 13% 
Gum: 371.4% 
Active pouch: 85.7% 
Gum: 26% 
Active pouch: 6% 
Gum: 4 
Active pouch: 17 
Mouth 
irritation 
37% Gum: 47% 
Active pouch: 50% 
Gum: 27% 
Active pouch: 35.1% 
Gum: 10% 
Active pouch: 13% 
Gum: 10 
Active pouch: 8 
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for mouth irritation was five for the lozenge, four for the gum, and two for the mouth 
spray (Table 7).  
Table 5. Mean change in craving from baseline to 60 minutes after taking medication7 
 
Table 6. Temporary smoking cessation until 5:30pm on study days7 
 
Table 7. Adverse effects of the lozenge, gum, and mouth spray vs. placebo7  
 
In the study by Shahab et al, 48 people participated in comparing the new 
Nicotine Cannon (NC) to pre-existing forms of NRT (lozenge, mini-lozenge, gum, and 
inhaler).  The researchers of this study did not provide the author with dichotomous data; 
therefore, NNT and NNH could not be calculated.  Shahab et al found that there were 
statistically significant reductions in both time spent with urges to smoke and strength of 
those urges from before NRT use to after NRT use across all types of NRT that were 
tested in this trial (p <0.0001) (Table 8).9  Compared to the lozenge, mini-lozenge, and 
Treatment Mean change Mean difference with placebo (95% 
CI) 
p-value 
Lozenge -24.7 -15.8 (-23.7 to -7.9) <0.0001 
Gum -25.8 -16.9 (-24.8 to -9.0) <0.0001 
Mouth spray -28.6 -19.7 (-27.6 to -11.7) <0.0001 
Placebo -8.9 ------------------ ------------------ 
CER EER RBI ABI NNT 
19% Lozenges: 45% Lozenges: 137% Lozenge: 26% Lozenge: 4 
 Gum: 55% Gum: 190% Gum: 36% Gum: 3 
 Mouth spray: 
53% 
Mouth spray: 179% Mouth spray: 
34% 
Mouth spray: 3 
Adverse 
 
CER EER RRI ARI NNH 
Feeling sick 4% Lozenge: 38% 
Gum: 34% 
Mouth spray: 36% 
Lozenge: 85% 
Gum: 80% 
Mouth spray: 75% 
Lozenge: 34% 
Gum: 30% 
Mouth spray: 32% 
Lozenge: 3 
Gum: 3 
Mouth spray: 3 
Mouth 
irritation 
4% Lozenge: 25% 
Gum: 30% 
Mouth spray: 45% 
Lozenge: 525% 
Gum: 650% 
Mouth spray: 1025% 
Lozenge: 21% 
Gum: 26% 
Mouth spray: 41% 
Lozenge: 5 
Gum: 4 
Mouth spray: 2 
10 
 
nicotine inhaler, NC usage resulted in less reported adverse side effects, making it more 
attractive to those who are interested in smoking cessation. 
Table 8. Reduction in withdrawal symptoms across all NRT products from before to after 
use9 
Withdrawal Symptom F-score p-value 
Time spent with urges (1, 236) = 27.5 <0.0001 
Strength of urges (1, 213) = 40.9 <0.0001 
   
DISCUSSION 
 In compiling the data across all three of the articles that were analyzed in this 
systematic review, the conclusion can be drawn that nicotine replacement therapy is more 
effective than placebo in preventing the withdrawal symptom of craving in smokers who 
are attempting to quit in the short term.  However, with the small sample sizes and short 
study times, it is impossible to make such a generalized statement about the long term 
usage of NRT and smoking cessation. 
Nicotine replacement therapy is widely available in the United States.  The 
transdermal patch, lozenges, and gum are all available over the counter and do not require 
a prescription.10 However, it is important to inform your doctor that you are attempting to 
quit smoking and using an over-the-counter NRT product.  The high amounts of nicotine 
in cigarettes change the body’s metabolism; therefore, removing tobacco products from 
one’s body may change the management of other chronic health problems. The mouth 
spray, nasal spray, and nicotine inhaler all require a prescription from a doctor, physician 
assistant, or other licensed medical provider.10  
One of the major roadblocks to NRT usage is insurance coverage.  Although it is 
improving, most private and state based insurances do not cover the entire cost of NRT.  
The American Lung Association has been making efforts to demonstrate how important it 
is for insurance companies to offer coverage for smoking cessation products.  Currently, 
11 
 
only six states require Medicaid to cover smoking cessation products and only nine states 
require private insurances to cover smoking cessation products.11 Last year, the federal 
government started providing coverage for smoking cessation products and counseling 
sessions for all of its employees.11 With additional support from insurance companies, 
smokers will have more of an incentive to quit their habit and prevent many of the health 
complications that result from long term tobacco use. 
 All three of the studies included in this review had similar limitations and flaws in 
the performance of the research. The sample size of less than 50 participants for each 
study did not allow for adequate heterogeneity in order to be able to make a general 
statement about the efficacy of NRT among all types of dependent smokers.  All three 
studies allowed the participants to smoke on the days in between the short 9-hour study 
days.  In reality, smokers are not supposed to alternate using NRT with smoking 
cigarettes.  Therefore, these studies did not adequately assess the correct usage of the 
products.  Long term usage of these products could lead to the development of more 
adverse reactions that may affect people’s compliance with the therapy.  
CONCLUSION 
 According to the three studies in this review, nicotine replacement therapy is a 
safe and effective treatment in preventing the withdrawal symptom of craving in 
dependent smokers who are attempting to quit.  However, the various limitations of the 
three included studies inhibit the author from generalizing the effectiveness of NRT to 
the entire population of dependent smokers.  In future studies, it will be important to 
increase the sample size and the length of time that the participants use the NRT 
products.  It is necessary to eliminate the series of non-study days in between study days 
in order to evaluate the correct usage of NRT.  It would be interesting to divide the 
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participants according to the length of time that they have been smoking and frequency of 
their habit to see if NRT works equally as well for those with a longer and heavier habit 
history than others.   Another possibility for further research would be to start a 
longitudinal study that assesses smoker’s health before attempting to quit, follows them 
through the quitting process, and then checks in with them at certain intervals to see how 
successful they were in the long term.  
Smoking cessation is a challenging and personal process; with continued research 
and support from insurance companies, dependent smokers will be able to successfully 
quit their habits and live healthier and longer lives.  
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